Money manager Cathie Wood’s Ark Invest has a favorite biotech holding now, going by the firm’s recent buying activity.
What Happened: Ark, through its flagship Ark Innovation ETF (NYSE:ARKK) and Ark Genomic Revolution ETF (CBOE: ARKG), has been brisk with its acquisition of Moderna, Inc. (NASDAQ:MRNA) shares in March. The latest purchase was on Wednesday when the two funds lapped up 90,627 Modena shares, valued at $9.34 million.
Ark’s current Moderna holdings are as follows:
Shares held Value of holding ARKK 518,756 $54.53M ARKG 377,014 $39.63M Total 895,770 $94.16M
Ark’s 13F report filed with the SEC in mid-January shows that the firm held 437,403 Moderna shares at the end of the fourth quarter, with the value of the holding at $43.50 million. Since the fourth quarter, the Wood-run firm’s Moderna stake has more than doubled.
Moderna is now the 19th biggest holding of ARKG and the 31st biggest holding of ARKK.
The Moderna buying spree this year began on March 11. Ark was a buyer again on March ...